HONG KONG (Reuters) - China's Shenzhen Kangtai Biological Products reported a net loss in 2022, hurt by waning demand for COVID-19 vaccine shots.
The decline from a net profit of 1.3 billion yuan ($191.71 million) in 2021 to net losses of up to 150 million yuan was mainly driven by weaker COVID vaccine demand, it said in a filing to the Shenzhen stock exchange.
($1 = 6.7810 Chinese yuan renminbi)
(Reporting by Meg Shen)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 20.75 CNY | +7.01% | +4.06% | 3.2B | ||
| 1,808 PTS | +1.78% | +2.49% | - | ||
| 7.267 CNH | 0.00% | +0.26% | - | ||
